The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for BioCardia Inc. (BCDA) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0001, or 0.01%, to $0.7201. The BioCardia Inc. has recorded 9,142 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules.
BioCardia Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $0.72 and fluctuated between $0.7700 as its day high and $0.7001 as its day low. The current market capitalization of BioCardia Inc. is $15.57M. A total of 0.97 million shares were traded on the day, compared to an average of 2.41M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, BCDA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 18 BUYs and 3 SELLs from insiders. Insiders purchased 1,528,975 shares during that period but sold 73,009.
In the most recent transaction, Altman Peter bought 6,200 shares of BCDA for 1.60 per share on May 26. After the transaction, the President and CEO now owns 469,239 company shares. In a previous transaction on Dec 16, FROST PHILLIP MD ET AL bought 595,238 shares at 1.68 per share. BCDA shares that 10% Owner owns now total 2,025,827.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for BCDA in the last 3 months, the mean price target is $4.00 with high estimates of $4.00 and low estimates of $4.00. In terms of 52-week highs and lows, BCDA has a high of $2.92 and a low of $0.36.
As of this writing, BCDA has an earnings estimate of -$0.12 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of -$0.1 per share and a lower estimate of -$0.14. The company reported an EPS of -$0.17 in the last quarter, which was -6.30% lower than expectations of -$0.16.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BCDA’s latest balance sheet shows that the firm has $12.87M in Cash & Short Term Investments as of fiscal 2021. There were $1.87M in debt and $3.71M in liabilities at the time. Its Book Value Per Share was -$0.03, while its Total Shareholder’s Equity was $10.38M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BCDA is Buy with a score of 4.00.